Top

Published in:

01-01-2021 | Prasugrel

PEAR1 polymorphisms as a prognostic factor in hemostasis and cardiovascular diseases

Authors: Narges Ansari, Sahar Najafi, Saied Shahrabi, Najmaldin Saki

Published in: Journal of Thrombosis and Thrombolysis | Issue 1/2021

Abstract

Platelet Endothelial Aggregation Receptor (PEAR1), as a platelet receptor, plays a vital role in hemostasis. This receptor, by its extracellular part, causes platelet adhesion and consequently initiates platelet aggregation. Dysfunction of PEAR1 can disrupt platelet aggregation in patients with cardiovascular diseases (CVDs). The content used in this paper has been taken from English language articles (2005–2020) retrieved from Pubmed database and Google scholar search engine using “Cardiovascular Disease”, “PEAR1”, “Polymorphism”, and “Platelet Aggregation” keywords. Some PEAR1 polymorphisms can disrupt homeostasis and interfere with the function mechanism of cardiac drugs. Since polymorphisms in this gene affect platelet function and the platelet aggregation process, PEAR1 could be further studied in the future as an essential factor in controlling the treatment process of patients with cardiovascular diseases. PEAR1 polymorphisms through disruption of the platelet aggregation process can be a risk factor in patients with CVDs. Therefore, controlling patients through genetic testing and the evaluation of PEAR1 polymorphisms can help improve the treatment process of patients. According to the studies on the PEAR1 gene and the effect of different polymorphisms on some crucial issues in CVDs patients (changes in platelet activity), it is clear that if there is a significant relationship between polymorphisms and CVDs, they can be used as prognostic and diagnostic markers. This study aims to evaluate the prognosis and drug treatment of the PEAR1 gene in CVDs patients.

Lavie CJ, Arena R, Alpert MA et al (2018) Management of cardiovascular diseases in patients with obesity. Nat Rev Cardiol 15(1):45CrossRef

Mozaffarian D, Benjamin EJ et al (2016) Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation 133(4):e38PubMed

Farré AL, Modrego J, Zamorano-León JJ (2014) Effects of hormones on platelet aggregation. Hormone Mol Biol Clin Investig 18(1):27–36CrossRef

Kim Y, Suktitipat B, Yanek LR et al (2013) Targeted deep resequencing identifies coding variants in the PEAR1 gene that play a role in platelet aggregation. PLoS ONE 8(5):e64179. https://doi.org/10.1371/journal.pone.0064179CrossRefPubMedPubMedCentral

Kauskot A, Di Michele M, Loyen S et al (2012) A novel mechanism of sustained platelet αIIbβ3 activation via PEAR1. Blood J Am Soc Hematol 119(17):4056–4065

Maleknia M, Valizadeh A, Pezeshki S et al (2019) Immunomodulation in leukemia: cellular aspects of anti-leukemic properties. Clin Transl Oncol 1–10

Faraday N, Yanek LR, Yang XP et al (2011) Identification of a specific intronic PEAR1 gene variant associated with greater platelet aggregability and protein expression. Blood 118(12):3367–3375. https://doi.org/10.1182/blood-2010-11-320788CrossRefPubMedPubMedCentral

Li M, Hu Y, Wen Z et al (2017) Association of PEAR1 rs12041331 polymorphism and pharmacodynamics of ticagrelor in healthy Chinese volunteers. Xenobiotica 47(12):1130–1138. https://doi.org/10.1080/00498254.2016.1271962CrossRefPubMed

Xu K, Ye S, Zhang S et al (2019) Impact of platelet endothelial aggregation receptor-1 genotypes on platelet reactivity and early cardiovascular outcomes in patients undergoing percutaneous coronary intervention and treated with aspirin and clopidogrel. Circulation 12(5):e007019PubMed

10.

Nanda N, Bao M, Lin H et al (2005) Platelet endothelial aggregation receptor 1 (PEAR1), a novel epidermal growth factor repeat-containing transmembrane receptor, participates in platelet contact-induced activation. J Biol Chem 280(26):24680–24689. https://doi.org/10.1074/jbc.M413411200CrossRefPubMed

11.

Pi L, Xu Y, Fu L et al (2019) A PEAR1 polymorphism (rs12041331) is associated with risk of coronary artery aneurysm in Kawasaki disease. Ann Hum Genet 83(1):54–62. https://doi.org/10.1111/ahg.12285CrossRefPubMed

12.

Sun Y, Vandenbriele C, Kauskot A et al (2015) A human platelet receptor protein microarray identifies the high affinity immunoglobulin E receptor subunit alpha (FcepsilonR1alpha) as an Activating Platelet Endothelium Aggregation Receptor 1 (PEAR1) ligand. Mol Cell Proteomics 14(5):1265–1274. https://doi.org/10.1074/mcp.M114.046946CrossRefPubMedPubMedCentral

13.

Criel M, Izzi B, Vandenbriele C et al (2016) Absence of Pear1 does not affect murine platelet function in vivo. Thrombosis Res 146:76–83. https://doi.org/10.1016/j.thromres.2016.08.026CrossRef

14.

Kauskot A, Vandenbriele C, Louwette S et al (2013) PEAR1 attenuates megakaryopoiesis via control of the PI3K/PTEN pathway. Blood 121(26):5208–5217. https://doi.org/10.1182/blood-2012-10-462887CrossRefPubMed

15.

Vandenbriele C, Sun Y, Criel M et al (2016) Dextran sulfate triggers platelet aggregation via direct activation of PEAR1. Platelets 27(4):365–372. https://doi.org/10.3109/09537104.2015.1111321CrossRefPubMed

16.

Nanda N, Phillips DR (2006) Novel targets for antithrombotic drug discovery. Blood Cells Mol Dis 36(2):228–231. https://doi.org/10.1016/j.bcmd.2005.12.026CrossRefPubMed

17.

Kardeby C, Fälker K, Haining EJ et al (2019) Synthetic glycopolymers and natural fucoidans cause human platelet aggregation via PEAR1 and GPIbα. Blood Adv 3(3):275–287CrossRef

18.

Yang WY, Petit T, Cauwenberghs N et al (2017) PEAR1 is not a major susceptibility gene for cardiovascular disease in a Flemish population. BMC Med Genet 18(1):45. https://doi.org/10.1186/s12881-017-0411-xCrossRefPubMedPubMedCentral

19.

Jones CI, Bray S, Garner SF et al (2009) A functional genomics approach reveals novel quantitative trait loci associated with platelet signaling pathways. Blood 114(7):1405–1416. https://doi.org/10.1182/blood-2009-02-202614CrossRefPubMed

20.

Elwood PC, Renaud S, Sharp DS et al (1991) Ischemic heart disease and platelet aggregation. Caerphilly Collab Heart Dis Stud 83(1):38–44

21.

Yao Y, Tang XF, Zhang JH et al (2016) Association of PEAR1 genetic variants with platelet reactivity in response to dual antiplatelet therapy with aspirin and clopidogrel in the Chinese patient population after percutaneous coronary intervention. Thromb Res 141:28–34. https://doi.org/10.1016/j.thromres.2016.02.031CrossRefPubMed

22.

Yao Y, Tang XF, He C et al (2018) Effect of PEAR1 genetic variants on 1-year outcomes in chinese patients with acute myocardial infarction after percutaneous coronary intervention. J Atheroscler Thromb 25(5):454–459. https://doi.org/10.5551/jat.39982CrossRefPubMedPubMedCentral

23.

Keramati AR, Yanek LR, Iyer K et al (2018) Targeted deep sequencing of the PEAR1 locus for platelet aggregation in European and African American families. Platelets 19:1–7. https://doi.org/10.1080/09537104.2018.1447659CrossRef

24.

Getz TM, Manne BK, Buitrago L et al (2013) Dextran sulphate induces fibrinogen receptor activation through a novel Syk-independent PI-3 kinase-mediated tyrosine kinase pathway in platelets. Thromb Haemost 109(6):1131–1140. https://doi.org/10.1160/th12-09-0645CrossRefPubMed

25.

Alshehri OM, Montague S, Watson S et al (2015) Activation of glycoprotein VI (GPVI) and C-type lectin-like receptor-2 (CLEC-2) underlies platelet activation by diesel exhaust particles and other charged/hydrophobic ligands. Biochem J 468(3):459–473. https://doi.org/10.1042/bj20150192CrossRefPubMed

26.

Kardeby C, Falker K, Haining EJ et al (2019) Synthetic glycopolymers and natural fucoidans cause human platelet aggregation via PEAR1 and GPIbalpha. Blood Adv 3(3):275–287. https://doi.org/10.1182/bloodadvances.2018024950CrossRefPubMedPubMedCentral

27.

Shahrabi S, Behzad MM, Jaseb K et al (1976) Thrombocytopenia in leukemia: pathogenesis and prognosis. Histol Histopathol 2018:11976–11981

28.

Shahrabi S, Maleknia M, Tavakolifar Y, et al (2019) Neutropenia and leukemia development: genetic risk factors and prognosis. 1–12.

29.

Xu K, Liu X, Ott J et al (2018) The combined effects of cardiovascular disease related SNPs on ischemic stroke. J Neurol Sci 388:141–145CrossRef

30.

Faraday N, Becker DM, Yanek LR et al (2006) Relation between atherosclerosis risk factors and aspirin resistance in a primary prevention population. Am J Cardiol 98(6):774–779. https://doi.org/10.1016/j.amjcard.2006.04.015CrossRefPubMed

31.

Herrera-Galeano JE, Becker DM, Wilson AF et al (2008) A novel variant in the platelet endothelial aggregation receptor-1 gene is associated with increased platelet aggregability. Arterioscl Thrombo Vasc Biol 28(8):1484–1490. https://doi.org/10.1161/atvbaha.108.168971CrossRef

32.

Wurtz M, Nissen PH, Grove EL et al (2014) Genetic determinants of on-aspirin platelet reactivity: focus on the influence of PEAR1. PLoS ONE 9(10):e111816. https://doi.org/10.1371/journal.pone.0111816CrossRefPubMedPubMedCentral

33.

Zhang S, Zhu J, Li H et al (2018) Study of the association of PEAR1, P2Y12, and UGT2A1 polymorphisms with platelet reactivity in response to dual antiplatelet therapy in Chinese patients. Cardiology 140(1):21–29CrossRef

34.

Nawarskas JJ, Montoya TN (2018) Switching from ticagrelor or prasugrel to clopidogrel. Cardiol Rev 26(2):107–111. https://doi.org/10.1097/crd.0000000000000181CrossRefPubMed

35.

Faraday N, Yanek LR, Mathias R et al (2007) Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1. Circulation 115(19):2490–2496. https://doi.org/10.1161/circulationaha.106.667584CrossRefPubMed

36.

Lewis JP, Ryan K, O’connell JR et al (2013) Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes clinical perspective. Circulation 6(2):184–192PubMed

37.

Izzi B, Noro F, Cludts K et al (2018) Cell-specific PEAR1 methylation studies reveal a locus that coordinates expression of multiple genes. Int J Mol Sci 19(4):1069. https://doi.org/10.3390/ijms19041069CrossRefPubMedCentral

38.

Johnson AD (2016) Pairing megakaryopoiesis methylation with PEAR1. Blood 128(7):890–892. https://doi.org/10.1182/blood-2016-06-723940CrossRefPubMedPubMedCentral

39.

Nie XY, Li JL, Qin SB et al (2018) Genetic mutations in PEAR1 associated with cardiovascular outcomes in Chinese patients with acute coronary syndrome. Thromb Res 163:77–82. https://doi.org/10.1016/j.thromres.2018.01.026CrossRefPubMed

40.

Xiang Q, Cui Y, Zhao X et al (2013) Identification of PEAR1 SNPs and their influences on the variation in prasugrel pharmacodynamics. Pharmacogenomics 14(10):1179–1189. https://doi.org/10.2217/pgs.13.108CrossRefPubMed

41.

Stimpfle F, Bauer M, Rath D et al (2018) Variants of PEAR1 are associated with outcome in patients with ACS and stable CAD undergoing PCI. Front Pharmacol 9:490CrossRef

42.

Olivi L, Vandenbriele C, Gu Y-M et al (2015) PEAR1 is not a human hypertension-susceptibility gene. Blodd Press 24(1):61–64CrossRef

43.

Roberts R, Stewart AF (2012) Genes and coronary artery disease: where are we? Am Coll Cardiol 60(18):1715–1721CrossRef

44.

Fisch AS, Yerges-Armstrong LM, Backman JD et al (2015) Genetic variation in the platelet endothelial aggregation receptor 1 gene results in endothelial dysfunction. PLoS ONE 10(9):e0138795. https://doi.org/10.1371/journal.pone.0138795CrossRefPubMedPubMedCentral

45.

Izzi B, Pistoni M, Cludts K et al (2016) Allele-specific DNA methylation reinforces PEAR1 enhancer activity. Blood 128(7):1003–1012. https://doi.org/10.1182/blood-2015-11-682153CrossRefPubMed

46.

Peng LL, Zhao YQ, Zhou ZY et al (2016) Associations of MDR1, TBXA2R, PLA2G7, and PEAR1 genetic polymorphisms with the platelet activity in Chinese ischemic stroke patients receiving aspirin therapy. Acta Pharmacol Sin 37(11):1442–1448. https://doi.org/10.1038/aps.2016.90CrossRefPubMedPubMedCentral

47.

Fu Y, Sun S, Liang J et al (2016) PEAR1 gene polymorphism in a Chinese pedigree with pulmonary thromboembolism. Medicine 95(51):e5687. https://doi.org/10.1097/md.0000000000005687CrossRefPubMedPubMedCentral

48.

Johnson AD, Yanek LR, Chen M-H et al (2010) Genome-wide meta-analyses identifies seven loci associated with platelet aggregation in response to agonists. Nat Genet 42(7):608CrossRef

Title: PEAR1 polymorphisms as a prognostic factor in hemostasis and cardiovascular diseases
Authors: Narges Ansari
Sahar Najafi
Saied Shahrabi
Najmaldin Saki
Publication date: 01-01-2021
Publisher: Springer US
Keyword: Prasugrel
Published in: Journal of Thrombosis and Thrombolysis / Issue 1/2021
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-020-02149-w

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

PEAR1 polymorphisms as a prognostic factor in hemostasis and cardiovascular diseases

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

Acute revascularization treatments for ischemic stroke in the Stroke Units of Triveneto, northeast Italy: time to treatment and functional outcomes

Ph− myeloproliferative neoplasms and the related risk factors for stroke occurrence: Results from a registry of patients treated with Anagrelide

Long-term outcome of patients with ST-segment elevation myocardial infarction treated with low-dose intracoronary thrombolysis during primary percutaneous coronary intervention: the 5-year results of the DISSOLUTION Trial

Stroke and left atrial thrombi after cryoballoon ablation of atrial fibrillation: incidence and predictors. Results from a long-term follow-up

Aortic thrombus in patients with severe COVID-19: review of three cases

Incidence of pulmonary embolism in non-critically ill COVID-19 patients. Predicting factors for a challenging diagnosis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page